Etablissement Français du Sang

Quick facts

Marketed products

• Additive solution
• Autologous plasma
• Pathogen reduction process · Hematology / Transfusion Medicine
  A pathogen reduction technology that inactivates viruses, bacteria, and other pathogens in blood products through chemical or physical treatment to improve transfusion safety.

Phase 1 pipeline

• Apheresis donation
• intravenous injection of labeled cRBC
• Whole blood donation

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Etablissement Français du Sang portfolio CI brief
• Etablissement Français du Sang pipeline updates RSS

Frequently asked questions about Etablissement Français du Sang

Related

• Additive solution
• Autologous plasma
• Pathogen reduction process · Hematology / Transfusion Medicine
• Sector hub: All tracked pharma companies